Clinical Trials are an important part of NETs research as they help provide new treatment options for NET patients. As with any medical information, please consult with your oncologist and medical team before making any changes in your medical treatment.
NorCal CarciNET provides the information on clinical trials as a convenience to our readers. The listing below and on the menus to the left may not be complete or up to date and you should visit ClinicalTrials.Gov to do additional research.
This study will evaluate members in families with a history of small bowel carcinoid cancer to study the natural history of those family members that have the disease, determine ways to improve early detection by performing surveillance on those at risk but without disease and to identify the gene(s) that may cause the tumors. Familial carcinoid tumors usually originate in hormone-producing cells that line the small intestine or other cells of the digestive tract. The tumors are slow-growing and usually take many years before they cause symptoms. It is known that these tumors occur more often in some families and are then passed from one generation to the next by inherited genes.
To learn more about this study click here to be taken to Clinical Trials.Gov
From Ipsen - results from CLARINET(R) Phase III clinical trial showed the antiproliferative effect of Somatuline(R) in the treatment of non-functioning GEP-NETs. Data showed that Somatuline(R) statistically significantly prolonged time to disease progression or death in non-functioning GEP-NET patients (p=0.0002; hazard ratio 0.47; 95% CI: 0.30-0.73
--After 2 years of treatment with Somatuline(R), disease progression or death was reduced by 53%: 62% of GEP-NET patients treated with Somatuline(R) had not progressed or died versus 22% with placebo
--Pre-specified subgroup analyses showed that the antiproliferative effect of Somatuline(R) is statistically significant in midgut tumors, clinically relevant in pancreatic NETs and independent of the tumor grade and hepatic tumor load
--Safety data generated from the study are consistent with known safety profile of Somatuline(R)
To download poster presented at NANETs meeting click here.
Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome is entering into a phase 3 trial after a successful phase II trial in Europe. The primary efficacy endpoint of the phase 2 trial was the reduction of bowel movements from baseline in patients with metastatic carcinoid syndrome who were refractory to or could not tolerate somatostatin analog therapy.
The phase III triall will be available at UCSF and Stanford.
Stanford is currently recruiting patients,
please click here for more information.
To learn more about the clinical trial please visit clinicaltrials.gov page.
To read more about the results from the phase 2 trial please visit the Lexicon-pharma webstie.
For more information on this trial see ClinicalTrials.gov